Please login to the form below

Not currently logged in

Shire promotes David Colpman to fill global business development role

He replaces Barbara Deptula, who is retiring from the biopharma company

Shire David Colpman global business developmentShire has made two senior promotions, appointing David Colpman to lead its global business development team and elevating Ann Judge to its leadership team.

Colpman will take over from Barbara Deptula, who is retiring after eight years at the helm of the Dublin-based biopharmaceutical company's business development team.

He has been with Shire for over 12 years, leading many of its significant deals, and before that worked at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals in a variety of business development and commercial roles.

Colpman began his industry career at ICI (now AstraZeneca) in formulation and manufacturing and in his new role will report to Shire's chief executive Angus Russell.

Meanwhile Shire has also appointed Ann Judge, currently senior vice president of its global Human Resources team, to the Shire leadership team.

Judge has over 20 years of global HR experience in the pharmaceutical, chemical, and oil and gas industries, having begun her career with Dow Chemical. She joined Shire to lead its global HR team in late 2010, after spending six years with Wyeth Pharmaceuticals (now part of Pfizer).

6th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...